RBC Capital raised the firm’s price target on Medtronic to $92 from $82 and keeps a Sector Perform rating on the shares as part of a broader research note previewing MedTech for 2024. The company has recently provided commentary that they saw positive procedure volume momentum in the quarter, and for the first few weeks of November, the analyst tells investors in a research note. Medtronic believes volumes are back to pre-COVID levels or better and noted that staffing issues should continue to decrease, RBC added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDT:
- Medtronic put volume heavy and directionally bearish
- Medtronic announces FDA approval of Percept RC DBS system
- Orchestra BioMed announces initiation of BACKBEAT study of AVIM therapy
- Medtronic announces CE Mark approval for MiniMed 780G system
- Comcast among forgotten value stocks with potential to grow, Barron’s says
